Zhifei BiologicalOn the evening of November 26, the company announced that its wholly-owned subsidiary, Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd., recently obtained an invention patent certificate issued by the United States Patent and Trademark Office. The patent, titled "Combined vaccine against human respiratory syncytial virus (RSV) infections and method thereof for inducing immune response," is patent number US12,472,243B2, with an estimated expiration date of July 29, 2042.

It is understood that the aforementioned invention patent was obtained by Zhifei Green Bamboo in collaboration with Beijing Jiaotong University during the development of a respiratory syncytial virus (RSV) vaccine.

Zhifei Biological Products Co., Ltd. stated that it has obtained its first patent certificate in the United States, laying the foundation for its global expansion. This patent certificate will further enhance the company's intellectual property rights.We will establish a protection system to fully leverage our independent intellectual property rights, promote technological innovation, advance the company's international development strategy, and enhance the company's core competitiveness.

https://finance.eastmoney.com/a/202511263575633079.html